Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.46 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8591229 | 0.93 | LTB4R (0.49) | LTB4RLTB4R2PTGS1PTGS2MT-CO1 | |
| SCHEMBL1345176 | 0.82 | PTGS1 (0.65) | PTGS1PTGS2MT-CO1MT-CO2CXCR1 | |
| SCHEMBL9063258 | 0.82 | PTGS1 (0.65) | PTGS1PTGS2MT-CO1MT-CO2CXCR1 | |
| SCHEMBL16191538 | 0.82 | EED (0.40) | ALDH1A1 | |
| SCHEMBL24307189 | 0.81 | PTGS1 (0.67) | PTGS1PTGS2MT-CO1MT-CO2CXCR1 | |
| SCHEMBL9063786 | 0.81 | PTGS1 (0.67) | PTGS1PTGS2MT-CO1MT-CO2CXCR1 | |
| SCHEMBL8590234 | 0.78 | PTGS1 (0.51) | LTB4RLTB4R2PTGS1PTGS2MT-CO2 | |
| SCHEMBL28780509 | 0.76 | LTB4R (0.43) | LTB4RLTB4R2PTGS1PTGS2MT-CO1 | |
| SCHEMBL11195436 | 0.76 | PTGS1 (0.47) | PTGS1PTGS2MT-CO1MT-CO2FAAH | |
| SCHEMBL11189116 | 0.76 | PTGS1 (0.47) | PTGS1PTGS2MT-CO1MT-CO2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229942-B1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | LTB4R 81/4885LTB4R2 50/4885PTGS1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.